|
|
News Breaks
|
November 22, 2011
|
| 08:02 EDT |  | PPHM |
| theflyonthewall.com: | Peregrine reports promising 23.2 month median survival for phase 2 trial | | Peregrine Pharmaceuticals announced 23.2 month median overall survival from a single-arm Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with locally advanced or metastatic breast cancer. In a separate published study using a similar chemotherapy regimen of carboplatin and paclitaxel, median OS was 16.0 months in a similar patient population. Currently, Peregrine's bavituximab is being evaluated in randomized Phase II trials in non-small cell lung cancer, pancreatic cancer, and hepatitis C virus, as well as in four investigator-sponsored trials in additional oncology indications, including HER2-negative metastatic breast cancer. :theflyonthewall.com |
|
|
News For PPHM From The Last 14 Days Check below for free stories on PPHM the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 21, 2012
|
| 09:00 EDT |  | PPHM |
| | 07:36 EDT | | PPHM |
|
|
|
|
|
Subscribe for More Information